Mental and Cognitive Health Library

Every article, presentation, spotlight, and news item we've tagged to Mental and Cognitive Health.

All Library Articles Presentations Spotlights News

Showing 49–72 of 128

SAGE Research on AgingApr 28, 2026

Non-Pharmacological Sleep Interventions for Dementia Caregivers; A Systematic Review of Randomized Controlled Trials

Dementia caregivers experience chronic sleep disruption that impairs their own health and caregiving capacity. Non-pharmacological interventions—behavioral modifications, cognitive techniques, and environmental adjustments—demonstrate measurable improvements in sleep quality and duration when implemented consistently, with secondary benefits to emotional regulation and stress resilience.

LT WireApr 21, 2026

AlzeCure completes Phase Ib study of ACD856

AlzeCure completed Phase Ib evaluation of ACD856, a candidate that modulates BDNF and NGF signaling across the blood-brain barrier. Preclinical evidence suggests neuroprotective and anti-inflammatory effects with potential disease-modifying capacity in cognitive decline and depression.

Nature AgingApr 3, 2026

The case for space as a model of accelerated aging

Spaceflight stressors including microgravity and radiation accelerate biological aging pathways in astronauts, providing a compressed model for studying age-related disease mechanisms. This natural experiment offers direct evidence of how extreme environmental conditions trigger aging processes that occur more gradually in terrestrial populations.

SAGE Research on AgingFeb 25, 2026

Supportive Environmental Features at Home as Proactive/Reactive Associates of Disability and Mortality Status in Older Adults

Supportive environmental features in homes—grab bars, accessible layouts, lighting modifications—correlate with reduced disability progression and mortality risk in older adults. Implementation patterns vary significantly, and proactive installation (before functional decline) shows stronger protective associations than reactive modification after disability emerges.

Nature AgingMar 6, 2026

Mining the prodrome of neurodegeneration

Transformer-based analysis of electronic health records identified five distinct subtypes of Alzheimer's and Parkinson's disease, each with unique clinical trajectories, comorbidities, and genetic profiles. This stratification approach enables more precise disease understanding and potentially more targeted intervention strategies across the neurodegenerative disease landscape.

Longevity.TechnologyMar 10, 2026

MindImmune lands ADDF funding to harness the immune system against Alzheimer’s

MindImmune Therapeutics secured $5 million from the Alzheimer's Drug Discovery Foundation to advance MITI-101, a therapeutic targeting peripheral immune cell migration into the brain rather than amyloid or tau pathology. The approach addresses neuroinflammation as a driver of neurodegeneration, with preclinical evidence showing that blocking CD11c-positive immune cells reduces synaptic deterioration markers.

Longevity.TechnologyApr 9, 2026

Annovis traces buntanetap’s road to Alzheimer’s

Buntanetap, Annovis Bio's investigational therapy, targets multiple neurotoxic proteins implicated in Alzheimer's and Parkinson's disease rather than a single pathway. This multi-target approach reflects an emerging recognition in longevity science that neurodegeneration involves systemic breakdown across multiple mechanisms, not isolated protein pathology.

Nature AgingMar 11, 2026

Microglia protein profiles in CSF across Alzheimer’s disease clinical stages

Analysis of microglial proteins in cerebrospinal fluid identifies distinct molecular signatures across Alzheimer's disease stages, offering potential biomarkers for earlier detection and disease progression tracking. These markers reflect immune cell activation patterns that precede symptomatic decline, enabling more precise stratification of disease trajectory.

Nature AgingFeb 26, 2026

Subtyping Alzheimer’s disease and Parkinson’s disease using longitudinal electronic health records

Machine learning analysis of UK health records identifies distinct subtypes of Alzheimer's and Parkinson's disease with shared clinical patterns and divergent genetic signatures. These subtypes enable earlier detection and inform disease-specific intervention strategies, moving beyond one-size-fits-all approaches to neurodegenerative disease management.

LT WireMar 20, 2026

AlzeCure presents new preclinical data on NeuroRestore ACD856

ACD856, a first-in-class Trk receptor modulator, demonstrates dose-dependent activation of neurotrophin signaling pathways in preclinical models, with concurrent neuroprotective and antidepressant effects. This mechanism addresses a significant comorbidity pattern in Alzheimer's disease pathology where cognitive decline and mood disturbance are mechanistically linked.

Longevity.TechnologyMar 20, 2026

ALZpath cements pTau217 as Alzheimer’s diagnosis frontrunner

ALZpath's pTau217 antibody is establishing itself as a standardized infrastructure tool for blood-based Alzheimer's diagnosis, with 29 presentations at AD/PD 2026 demonstrating reproducibility across multiple research settings and clinical developers. The significance lies not in pTau217's promise alone, but in its emerging role as a scalable, platform-agnostic diagnostic that can integrate into routine medical practice rather than remain confined to specialized labs.

Wiley Aging CellApr 14, 2026

Frailty and Brain Myelin Across Adulthood: Multimodal MRI Insights From the BLSA

Frailty, measured by a validated Frailty Index, correlates with reduced myelin content across white matter tracts in adults from age 22 to 94, with the strongest associations in long-range projection fibers. This multimodal MRI evidence suggests myelin degradation may represent a neural substrate of systemic aging and physiological vulnerability.

The Lancet Healthy LongevityMar 27, 2026

[Articles] Delirium, long-term conditions, and incident dementia in older adults admitted to hospital for emergency care in Lothian, Scotland: a population-based cohort study

Delirium during hospitalization carries a substantial dementia risk in older adults, particularly those without multiple long-term conditions. The association suggests delirium represents either a marker of underlying neurodegeneration or a direct contributor to cognitive decline, warranting systematic assessment protocols in acute care settings.

SAGE Research on AgingFeb 28, 2026

Promoting Adaptation to Caregiving Challenges: A Qualitative Study of Dementia Caregiving Specialists

Dementia caregiving specialists employ structured approaches to help family caregivers develop mastery over the behavioral and emotional challenges of dementia care. Understanding how these specialists facilitate caregiver adaptation provides actionable insights for reducing caregiver burden and improving outcomes in neurodegenerative disease management.

Longevity.TechnologyApr 15, 2026

Lecanemab’s next phase: real-world treatment

Lecanemab is transitioning from controlled trials into real-world clinical practice, with Eisai presenting 14 studies on long-term outcomes, administration routes, and early intervention strategies. The data addresses whether cognitive benefits persist over extended periods and whether earlier detection and treatment can alter disease progression in what researchers term 'smoldering' Alzheimer's disease.

The Lancet Healthy LongevityMar 4, 2026

[Articles] Multidomain post-stroke cognitive impairment: development and validation of a clinical prediction model

Stroke-specific cognitive prediction models that assess multidomain impairment offer more accurate prognostic value than general cognitive decline models. The binary and continuous versions developed in this research demonstrate generalisability across diverse stroke populations and warrant further domain-specific refinement.

The Lancet Healthy LongevityApr 9, 2026

[Comment] Severe infections consistently linked to dementia?

Severe infections show a persistent association with dementia risk that remains significant even after adjusting for frailty and age-related conditions, suggesting the connection operates through mechanisms independent of pre-existing disease burden. This finding extends prior research and points toward infection-related pathways that directly influence cognitive decline.

Longevity.TechnologyMay 4, 2026

Buntanetap gains ground in new Alzheimer’s trial results

Buntanetap showed statistically significant cognitive improvements in early-stage Alzheimer's patients who tested positive for pTau217, reducing multiple disease-related biomarkers including tau, TDP-43, and neuroinflammatory signals. The drug's mechanism of blocking protein production upstream in the disease cascade, rather than targeting single endpoints, represents a shift toward earlier intervention and suggests the field is moving toward precision treatment based on underlying pathology rather than symptom presentation alone.

SAGE Research on AgingMar 23, 2026

Examining the Role of Dementia Worry in the Caregiver Burden Process

Dementia worry among family caregivers intensifies caregiver burden through increased stress and emotional strain, with anxiety about personal cognitive decline amplifying the physiological and psychological toll of caregiving responsibilities. This dynamic represents a critical but often-unmeasured pathway through which caregiver stress translates into health deterioration.

Nature AgingApr 14, 2026

Astrocyte-based CAR immunotherapy against Alzheimer’s disease

Engineered astrocytes equipped with chimeric antigen receptor technology can target amyloid-β and tau pathology in Alzheimer's disease models, offering a cell-based immunotherapy approach that addresses hallmark neuropathological features. This represents a distinct mechanistic strategy for modulating neuroinflammation and clearing pathogenic protein aggregates implicated in cognitive decline.

Nature AgingFeb 11, 2026

Exploratory analyses of clinical outcomes from the BIIB080 phase 1b study in mild Alzheimer’s disease

BIIB080, an antisense oligonucleotide targeting tau protein aggregation, demonstrated favorable trends in slowing cognitive and functional decline in a phase 1b trial of mild Alzheimer's disease patients. These exploratory findings support progression to larger efficacy trials and represent a mechanistic approach to tau-mediated neurodegeneration.

SAGE Research on AgingMar 14, 2026

Adequacy, Availability, and Awareness of Alzheimer’s Disease Resources Among Extension Professionals in Texas: Is There an Urban-Rural Divide?

Rural Extension professionals report significant gaps in Alzheimer's disease resources and dementia literacy compared to urban counterparts, with disparities in access to educational materials, diagnostic support, and caregiver services. These findings identify a structural barrier to early detection and management of cognitive decline in populations already at higher risk due to demographic and healthcare infrastructure constraints.

The Lancet Healthy LongevityFeb 9, 2026

[Articles] Delirium and adverse clinical outcomes: a matched cohort study in the UK Biobank

In-hospital delirium shows a dose-responsive association with adverse long-term clinical outcomes independent of frailty or pre-existing dementia, positioning it as a marker of sustained vulnerability rather than a transient acute event. This distinction matters for risk stratification and post-discharge intervention planning.

Longevity.TechnologyApr 10, 2026

NeuroTherapia clears Phase 2a in novel Alzheimer’s treatment

NeuroTherapia's oral Alzheimer's candidate NTRX-07 completed Phase 2a with safety clearance and early signals suggesting effects on neuroinflammation, the chronic immune dysregulation increasingly recognized as a major driver of cognitive decline. The drug targets brain inflammation rather than amyloid alone, representing a shift toward multi-system disease understanding.

Biological EDGE

Biohacking Starts With NO